The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Real-time multimodal AI for early risk prediction in BCMA CAR-T–treated myeloma
Ciara Freeman, MD, PhD, Moffitt Cancer Center, Tampa, FL, discusses the development of a real-time, multimodal artificial intelligence (AI) platform that integrates clinical, serologic, cytogenetic, and quantitative imaging data to improve early risk prediction in BCMA CAR-T–treated multiple myeloma (MM). Dr Freeman notes that combining these factors enhances the model’s discriminative power, enabling better identification of patients who will have good or poor outcomes with CAR T-cell therapy and guiding physician decision-making in the future. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
